Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

ICU TopicsAntimicrobial therapy

ICU · Antimicrobial therapy

Antimicrobial Therapy and Stewardship in the ICU

Also known as Antibiotic stewardship · Antimicrobial therapy · PK PD dosing · De-escalation · Antibiogram · Therapeutic drug monitoring · Antibiotic resistance

Antimicrobial stewardship is the systematic, the evidence-based, the measured use of the antibiotics to maximise the patient outcome, minimise the resistance, and reduce the toxicity. This topic builds the examiner's framework on the PK/PD dosing principles (the beta-lactam prolonged infusion, the aminoglycoside once-daily, the vancomycin AUC), the empirical therapy guided by the local antibiogram, the de-escalation when the culture returns, the duration of therapy (the shortest effective course), the beta-lactam allergy, the therapeutic drug monitoring, and the resistance mechanisms (the ESBL, the CRE, the MRSA, the VRE).

medium25 referencesUpdated 20 Aug 202610 min readVerification in progress

Practise this topic

  • 8 MCQs

Your progress

Saved on this device.

Practise this topic8 MCQs with explanations

Target exams

CICMFFICMEDICESICMSociety_CCM
On this page
Study tools

Your progress

Saved on this device.

Practise this topic8 MCQs with explanations

Target exams

CICMFFICMEDICESICMSociety_CCM
The one-line answer

Antimicrobial stewardship is the right drug, right dose, right duration, right de-escalation, and the right stop. The empirical cover is guided by the source, the local antibiogram, and the MDR risk; the dose is guided by PK and PD — the beta-lactam prolonged infusion for time-dependent, the aminoglycoside once-daily for concentration-dependent, the vancomycin AUC for the AUC-to-MIC ratio. De-escalation at 48 to 72 hours narrows to the culture. The duration is the shortest effective course (7 to 8 days for VAP, 4 days for intra-abdominal after source control, 14 days minimum for S. aureus bacteraemia). Procalcitonin guides the stop, never the start.[1][4]

Meet the patient

A 68-year-old nursing-home resident is admitted to ICU with septic shock (MAP 55 on a noradrenaline infusion, lactate 4.2) and severe community-acquired pneumonia. She has CKD (eGFR 30) and was treated with amoxicillin-clavulanate for a UTI 2 weeks ago. She reports a penicillin allergy (rash as a child). Blood cultures are drawn.[6]

The two questions that decide her first hour are the two that decide every antibiotic start: what covers her? and how do I dose it for her physiology? The first is answered by the source, the local antibiogram, and her MDR risk. The second is answered by PK and PD — the loading dose, the prolonged infusion, the renal adjustment. Start smart, then focus.[6]

ICU Fellowship (CICM) Pro

Continue reading

You have read the opening of this topic. The complete unit — every section and its primary-source references — is part of the ICU Fellowship (CICM) fellowship library.

Sign in to continueSee pricing
References25ShowHide
  1. [1]Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial Lancet, 2010.PMID 20097417
  2. [2]Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections Cochrane Database Syst Rev, 2017.PMID 29025194
  3. [3]Schuetz P, Bolliger R, Merker M, Christ-Crain M Procalcitonin-guided antibiotic therapy algorithms for different types of acute respiratory infections based on previous trials Expert Rev Anti Infect Ther, 2018.PMID 29969320
  4. [4]Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial JAMA, 2003.PMID 14625336
  5. [5]Sawyer RG, Claridge JA, Nathens AB, et al. Trial of short-course antimicrobial therapy for intraabdominal infection N Engl J Med, 2015.PMID 25992746
  6. [6]Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America Am J Respir Crit Care Med, 2019.PMID 31573350
  7. [7]Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society Clin Infect Dis, 2016.PMID 27418577
  8. [8]Rybak MJ, Le J, Lodise TP, et al. Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists Clin Infect Dis, 2020.PMID 32658968
  9. [9]Dulhunty JM, Roberts JA, Davis JS, et al. A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis Am J Respir Crit Care Med, 2015.PMID 26200166
  10. [10]Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial Clin Infect Dis, 2013.PMID 23074313
  11. [11]Udy AA, Dulhunty JM, Roberts JA, et al. Association between augmented renal clearance and clinical outcomes in patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial Int J Antimicrob Agents, 2017.PMID 28286115
  12. [12]Kasiakou SK, Sermaides GJ, Michalopoulos A, et al. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials Lancet Infect Dis, 2005.PMID 16122681
  13. [13]Boussekey N, Leroy O, Alfandari S, et al. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia Intensive Care Med, 2006.PMID 16477418
  14. [14]Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary Clin Infect Dis, 2011.PMID 21217178
  15. [15]Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance Clin Microbiol Infect, 2012.PMID 21793988
  16. [16]Gutiérrez-Pizarraya A, Leone M, Garnacho-Montero J, et al. Collaborative approach of individual participant data of prospective studies of de-escalation in non-immunosuppressed critically ill patients with sepsis Expert Rev Clin Pharmacol, 2017.PMID 28266901
  17. [17]Daghmouri MA, Dudoignon E, Chaouch MA, et al. Comparison of a short versus long-course antibiotic therapy for ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trials EClinicalMedicine, 2023.PMID 36911269
  18. [18]Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock Crit Care Med, 2006.PMID 16625125
  19. [19]Pagkalis S, Mantadakis E, Mavros MN, et al. Pharmacological considerations for the proper clinical use of aminoglycosides Drugs, 2011.PMID 22085385
  20. [20]Wu CC, Su YC, Wu KS, et al. Loading dose and efficacy of continuous or extended infusion of beta-lactams compared with intermittent administration in patients with critical illnesses: a subgroup meta-analysis and meta-regression analysis J Clin Pharm Ther, 2021.PMID 33135261
  21. [21]Ueda T, Takesue Y, Nakajima K, et al. Vancomycin loading dose is associated with increased early clinical response without attainment of initial target trough concentration at a steady state in patients with methicillin-resistant Staphylococcus aureus infections J Clin Pharm Ther, 2020.PMID 32301537
  22. [22]Legg A, Devchand F, Gwee A, et al. Safe and effective use of vancomycin Aust Prescr, 2025.PMID 40343139
  23. [23]Maan G, Keitoku K, Kimura N, et al. Cefepime-induced neurotoxicity: systematic review J Antimicrob Chemother, 2022.PMID 35971666
  24. [24]Caruso C, Valluzzi RL, Colantuono S, et al. Beta-Lactam Allergy and Cross-Reactivity: A Clinician's Guide to Selecting an Alternative Antibiotic J Asthma Allergy, 2021.PMID 33500632
  25. [25]Cattaneo D, Marriott DJ, Gervasoni C Hematological toxicities associated with linezolid therapy in adults: key findings and clinical considerations Expert Rev Clin Pharmacol, 2023.PMID 36787631

Test yourself

Practise what you just read

  • 8 MCQs
ICU Fellowship (CICM) Pro

$29/ monthor $279 / year

The complete ICU Fellowship (CICM) library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousTropical infections in ICU: melioidosis, leptospirosis, typhoidInfectiousNextApplied Pharmacology — Vasoactives, Sedatives and ParalysersApplied pharmacology